nimesulide has been researched along with Carcinoma, Non-Small Cell Lung in 8 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lung cancer is the leading cause of cancer-related deaths in the United States." | 1.33 | Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. ( Fang, F; Grimes, KR; St Clair, WH; Warren, GW; Xu, Y, 2006) |
| "Nimesulide was formulated into a metered dose inhaler (MDI) formulation and characterized for aerodynamic particle size and medication delivery." | 1.32 | Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. ( Chatterjee, A; Haynes, A; Shaik, MS; Singh, M, 2003) |
| "To study the effects of cyclooxygenase 2 selective inhibitor Nimesulide (NIM) combined with Cisplatin (DDP) on human lung cancer and the possible mechanisms, the proliferation and apoptosis of human lung cancer cell line A549 were evaluated by MTT reduction assay and flow cytometry respectively." | 1.32 | The effects of nimesulide combined with cisplatin on lung cancer. ( Liu, J; Xing, L; Xu, Y; Zhang, H; Zhang, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serresi, M | 1 |
| Siteur, B | 1 |
| Hulsman, D | 1 |
| Company, C | 1 |
| Schmitt, MJ | 1 |
| Lieftink, C | 1 |
| Morris, B | 1 |
| Cesaroni, M | 1 |
| Proost, N | 1 |
| Beijersbergen, RL | 1 |
| van Lohuizen, M | 1 |
| Gargiulo, G | 1 |
| Kim, BM | 1 |
| Won, J | 1 |
| Maeng, KA | 1 |
| Han, YS | 1 |
| Yun, YS | 1 |
| Hong, SH | 1 |
| Haynes, A | 1 |
| Shaik, MS | 1 |
| Chatterjee, A | 1 |
| Singh, M | 1 |
| Xing, L | 1 |
| Zhang, Z | 1 |
| Xu, Y | 2 |
| Zhang, H | 1 |
| Liu, J | 1 |
| Han, S | 2 |
| Roman, J | 2 |
| Grimes, KR | 1 |
| Warren, GW | 1 |
| Fang, F | 1 |
| St Clair, WH | 1 |
| Hida, T | 1 |
| Kozaki, K | 1 |
| Muramatsu, H | 1 |
| Masuda, A | 1 |
| Shimizu, S | 1 |
| Mitsudomi, T | 1 |
| Sugiura, T | 1 |
| Ogawa, M | 1 |
| Takahashi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
8 other studies available for nimesulide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.
Topics: A549 Cells; Animals; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Enhancer of Zes | 2018 |
Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Cell Line, Tumor; Cyclooxygenase 2 In | 2009 |
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.
Topics: Aerosols; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; | 2003 |
The effects of nimesulide combined with cisplatin on lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplat | 2004 |
COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cyclooxygenase Inhibitors; Extracellular Signal-Regul | 2005 |
COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase Inhibitors; Flavonoids; | 2006 |
Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality | 2006 |
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cyclooxygenase 2; C | 2000 |